Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KCNH2 | Q12809 | 1/20 | 0.32 |
| ▸ | TMEM97 | Q5BJF2 | 1/20 | 0.32 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.32 |
| ▸ | DPP4 | P27487 | 1/20 | 0.32 |
| ▸ | DPP8 | Q6V1X1 | 1/20 | 0.32 |
| ▸ | DPP9 | Q86TI2 | 1/20 | 0.32 |
| ▸ | DPP7 | Q9UHL4 | 1/20 | 0.32 |
| ▸ | CDK4 | P11802 | 1/20 | 0.30 |
| ▸ | CDK2 | P24941 | 1/20 | 0.30 |
| ▸ | CDK6 | Q00534 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL27251619 | 0.80 | EGFR (0.32) | — | |
| SCHEMBL20651755 | 0.79 | DRD2 (0.33) | — | |
| SCHEMBL20651756 | 0.78 | SLC6A9 (0.42) | — | |
| SCHEMBL19504663 | 0.76 | DRD2 (0.36) | — | |
| SCHEMBL19080440 | 0.71 | CDK1 (0.32) | CDK4 | |
| SCHEMBL19504487 | 0.70 | HRH3 (0.40) | — | |
| SCHEMBL22221914 | 0.69 | MEN1 (0.36) | KCNH2TMEM97SIGMAR1 | |
| SCHEMBL19505171 | 0.69 | TIPARP (0.47) | KCNH2 | |
| SCHEMBL19163917 | 0.69 | SMN1; SMN2 (0.35) | — | |
| SCHEMBL9963375 | 0.69 | DPP8 (0.46) | KCNH2DPP8DPP9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10858347-B2 | Multicyclic compounds and uses thereof | Karyopharm Therapeutics Inc. (US) | 2020-12-08 | — | — | US | disclosed |
| US-20190016710-A1 | MULTICYCLIC COMPOUNDS AND USES THEREOF | Karyopharm Therapeutics Inc. | 2019-01-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190016710-A1 | MULTICYCLIC COMPOUNDS AND USES THEREOF | MALT1, BCL9, BCL6 | KCNH2 515/4885TMEM97 2833/4885SIGMAR1 3645/4885 |
| US-10858347-B2 | Multicyclic compounds and uses thereof | MALT1, BCL9, BCL6 | KCNH2 515/4885TMEM97 2833/4885SIGMAR1 3645/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.